A ‘LIFE-SAVING’ jab for severe asthma that could prevent deadly attacks with just two doses a year could be available to patients in the UK within months. Depemokimab – developed by the drug giant GlaxoSmithKline – was given the green light by the Medicines and Healthcare Products Regulatory Agency (MHRA) this month. The “ultra long-acting”…
